<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.biopharminternational.com/view/-immunotherapy-alone-spares-dmmr-rectal-cancer-patients-the-lasting-effects-of-standard-treatment-says-msk-s-andrea-cercek</loc>
      <lastmod>2026-11-20T20:14:47.517Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T20:14:47.517Z</news:publication_date>
        <news:title><![CDATA[Immunotherapy Alone Spares dMMR Rectal Cancer Patients the Lasting Effects of Standard Treatment, Says MSK's Andrea Cercek]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-long-term-survival-data-for-a-pd-l1-4-1bb-bispecific-celldex-exits-atopic-dermatitis-and-a-fc-fusion-glp-1-goes-global</loc>
      <lastmod>2026-11-19T19:43:58.690Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T19:32:49.937Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/leads-biolabs-details-long-term-survival-data-and-2027-adc-combination-plans-for-pd-l1-4-1bb-bispecific-opamtistomig</loc>
      <lastmod>2026-11-20T19:03:31.893Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T19:03:31.893Z</news:publication_date>
        <news:title><![CDATA[Leads Biolabs Details Long-Term Survival Data and 2027 ADC Combination Plans for PD-L1/4-1BB Bispecific Opamtistomig]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/celldex-ends-program-for-its-atopic-dermatitis-treatment-after-phase-2-miss-points-to-limited-role-for-mast-cells</loc>
      <lastmod>2026-11-20T17:35:35.692Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T17:35:35.692Z</news:publication_date>
        <news:title><![CDATA[Celldex Ends Program for its Atopic Dermatitis Treatment After Phase 2 Miss Points to Limited Role for Mast Cells]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/innogen-arcera-licensing-efsubaglutide-alfa-glp-1-international-markets</loc>
      <lastmod>2026-11-20T15:22:49Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T15:22:49Z</news:publication_date>
        <news:title><![CDATA[Innogen Licenses GLP-1 Efsubaglutide Alfa to Arcera in $1 Billion Deal]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/merck-sac-tmt-trofuse-015-overall-survival-gastroesophageal-adenocarcinoma</loc>
      <lastmod>2026-11-20T14:57:04Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T14:57:04Z</news:publication_date>
        <news:title><![CDATA[Merck TROP2 ADC Meets Survival End Point in Gastroesophageal Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/simtra-biopharma-solutions-opens-250-million-building-h-to-expand-sterile-injectable-capacity-in-bloomington</loc>
      <lastmod>2026-11-19T21:35:30.490Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T21:35:30.490Z</news:publication_date>
        <news:title><![CDATA[Simtra BioPharma Solutions Opens $250 Million Building H to Expand Sterile Injectable Capacity in Bloomington]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/q-a-with-dr-mazen-noureddin-once-monthly-efimosfermin-and-fibrosis-improvement-in-mash</loc>
      <lastmod>2026-11-19T20:49:35.235Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T20:49:35.235Z</news:publication_date>
        <news:title><![CDATA[Q&A with Dr. Mazen Noureddin: Once-Monthly Efimosfermin and Fibrosis Improvement in MASH]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/application-note-validation-of-hamilton-tcd-sensor-during-pichia-pastoris-fermentation</loc>
      <lastmod>2026-11-19T20:32:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T20:32:00Z</news:publication_date>
        <news:title><![CDATA[Application Note - Validation of Hamilton TCD Sensor During Pichia pastoris Fermentation]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/application-note-in-line-turbidity-measurement-to-monitor-clarification-efficiency-in-cell-culture-harvests</loc>
      <lastmod>2026-11-19T20:32:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T20:32:00Z</news:publication_date>
        <news:title><![CDATA[Application Note - In-line Turbidity Measurement to Monitor Clarification Efficiency in Cell Culture Harvests]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-a-matrix-targeting-adc-in-head-and-neck-cancer-an-rnai-approval-in-myasthenia-gravis-and-abbvie-bets-on-and-gated-bispecifics</loc>
      <lastmod>2026-11-19T19:43:58.690Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:43:53.694Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/why-dmmr-rectal-tumors-respond-to-pd-1-blockade-alone-says-msk-s-andrea-cercek</loc>
      <lastmod>2026-11-19T19:43:09.311Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:43:09.311Z</news:publication_date>
        <news:title><![CDATA[Why dMMR Rectal Tumors Respond to PD-1 Blockade Alone, Says MSK's Andrea Cercek]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/pyxis-matrix-targeting-adc-micvo-shows-39-response-rate-and-9-2-month-median-response-duration-in-previously-treated-head-and-neck-cancer</loc>
      <lastmod>2026-11-19T15:56:45.413Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:56:40.465Z</news:publication_date>
        <news:title><![CDATA[Pyxis’ Matrix-Targeting ADC MICVO Shows 39% Response Rate and 9.2-Month Median Response Duration in Previously Treated Head and Neck Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/fda-approves-cemdisiran-livsayis-first-rnai-therapy-myasthenia-gravis</loc>
      <lastmod>2026-11-19T14:48:35Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:48:35Z</news:publication_date>
        <news:title><![CDATA[FDA Approves First RNAi Therapeutic for Generalized Myasthenia Gravis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/abbvie-and-disco-partner-on-and-gated-bispecifics-designed-to-recognize-tumor-selective-protein-pairs</loc>
      <lastmod>2026-11-19T14:37:08.614Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:37:08.614Z</news:publication_date>
        <news:title><![CDATA[AbbVie and DISCO Partner on AND-Gated Bispecifics Designed to Recognize Tumor-Selective Protein Pairs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/evotec-bristol-myers-squibb-second-ind-acceptance-celmod-molecular-glue-degrader</loc>
      <lastmod>2026-11-19T14:27:12Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:27:12Z</news:publication_date>
        <news:title><![CDATA[Evotec, BMS Gain Second FDA IND Acceptance for Molecular Glue Degrader]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-a-first-for-streamlined-biosimilar-approval-a-head-to-head-bispecific-trial-in-wet-amd-and-in-vivo-kir-car-t</loc>
      <lastmod>2026-11-17T21:52:14.074Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:30:52.987Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T]]></news:title>
      </news:news>
	</url></urlset>